Bryan B Edwards1, Alexander S Fairman2, Jeffrey E Cohen3, John W MacArthur3, Andrew B Goldstone3, Jeffrey B Woo1, William Hiesinger2, Y Joseph Woo4. 1. Department of Cardiothoracic Surgery, Stanford University School of Medicine, Stanford, Calif. 2. Division of Cardiovascular Surgery, Department of Surgery, Hospital of the University of Pennsylvania, Philadelphia, Pa. 3. Department of Cardiothoracic Surgery, Stanford University School of Medicine, Stanford, Calif; Division of Cardiovascular Surgery, Department of Surgery, Hospital of the University of Pennsylvania, Philadelphia, Pa. 4. Department of Cardiothoracic Surgery, Stanford University School of Medicine, Stanford, Calif. Electronic address: joswoo@stanford.edu.
Abstract
BACKGROUND: Despite promising therapeutic innovation over the last decade, peripheral arterial disease remains a prevalent morbidity, as many patients are still challenged with peripheral ischemia. We hypothesized that delivery of engineered stromal cell-derived factor 1-alpha (ESA) in an ischemic hind limb will yield significant improvement in perfusion. METHODS: Male rats underwent right femoral artery ligation, and animals were randomized to receive a 100 μL injection of saline (n = 9) or 6 μg/kg dosage of equal volume of ESA (n = 12) into the ipsilateral quadriceps muscle. Both groups of animals were also given an intraperitoneal injection of 40 μg/kg of granulocyte macrophage colony-stimulating factor (GMCSF). Perfusion was quantified using a laser Doppler imaging device preoperatively, and on postoperative days 0, 7, and 14. Immunohistochemistry was performed to quantify angiogenesis on day 14, and an mRNA profile was evaluated for angiogenic and inflammatory markers. RESULTS: Compared with the saline/GMCSF group at day 14, the ESA/GMCSF-injected animals had greater reperfusion ratios (Saline/GMCSF, 0.600 ± 0.140 vs ESA/GMCSF, 0.900 ± 0.181; group effect P = .006; time effect P < .0001; group×time effect P < .0001), elevated capillary density (10×; Saline/GMCSF, 6.40 ± 2.01 vs ESA/GMCSF, 18.55 ± 5.30; P < .01), and increased mRNA levels of vascular endothelial growth factor-A (Saline/GMCSF [n = 6], 0.298 ± 0.205 vs ESA/GMCSF [n = 8], 0.456 ± 0.139; P = .03). CONCLUSIONS: Delivery of ESA significantly improves perfusion in a rat model of peripheral arterial disease via improved neovasculogenesis, a finding which may prove beneficial in the treatment strategy for this debilitating disease.
BACKGROUND: Despite promising therapeutic innovation over the last decade, peripheral arterial disease remains a prevalent morbidity, as many patients are still challenged with peripheral ischemia. We hypothesized that delivery of engineered stromal cell-derived factor 1-alpha (ESA) in an ischemic hind limb will yield significant improvement in perfusion. METHODS: Male rats underwent right femoral artery ligation, and animals were randomized to receive a 100 μL injection of saline (n = 9) or 6 μg/kg dosage of equal volume of ESA (n = 12) into the ipsilateral quadriceps muscle. Both groups of animals were also given an intraperitoneal injection of 40 μg/kg of granulocyte macrophage colony-stimulating factor (GMCSF). Perfusion was quantified using a laser Doppler imaging device preoperatively, and on postoperative days 0, 7, and 14. Immunohistochemistry was performed to quantify angiogenesis on day 14, and an mRNA profile was evaluated for angiogenic and inflammatory markers. RESULTS: Compared with the saline/GMCSF group at day 14, the ESA/GMCSF-injected animals had greater reperfusion ratios (Saline/GMCSF, 0.600 ± 0.140 vs ESA/GMCSF, 0.900 ± 0.181; group effect P = .006; time effect P < .0001; group×time effect P < .0001), elevated capillary density (10×; Saline/GMCSF, 6.40 ± 2.01 vs ESA/GMCSF, 18.55 ± 5.30; P < .01), and increased mRNA levels of vascular endothelial growth factor-A (Saline/GMCSF [n = 6], 0.298 ± 0.205 vs ESA/GMCSF [n = 8], 0.456 ± 0.139; P = .03). CONCLUSIONS: Delivery of ESA significantly improves perfusion in a rat model of peripheral arterial disease via improved neovasculogenesis, a finding which may prove beneficial in the treatment strategy for this debilitating disease.
Authors: Sandra Herzog; Hendrik Sager; Eugen Khmelevski; Andrea Deylig; Wulf D Ito Journal: Am J Physiol Heart Circ Physiol Date: 2002-11 Impact factor: 4.733
Authors: Pavan Atluri; George P Liao; Corinna M Panlilio; Vivian M Hsu; Matthew J Leskowitz; Kevin J Morine; Jeffrey E Cohen; Mark F Berry; Erik E Suarez; Danielle A Murphy; William M F Lee; Timothy J Gardner; H Lee Sweeney; Y Joseph Woo Journal: Ann Thorac Surg Date: 2006-05 Impact factor: 4.330
Authors: Elisa A Liehn; Nancy Tuchscheerer; Isabella Kanzler; Maik Drechsler; Line Fraemohs; Alexander Schuh; Rory R Koenen; Simone Zander; Oliver Soehnlein; Mihail Hristov; Gabriela Grigorescu; Andreea O Urs; Mircea Leabu; Ilie Bucur; Marc W Merx; Alma Zernecke; Josef Ehling; Felix Gremse; Twan Lammers; Fabian Kiessling; Jürgen Bernhagen; Andreas Schober; Christian Weber Journal: J Am Coll Cardiol Date: 2011-11-29 Impact factor: 24.094
Authors: T Asahara; T Murohara; A Sullivan; M Silver; R van der Zee; T Li; B Witzenbichler; G Schatteman; J M Isner Journal: Science Date: 1997-02-14 Impact factor: 47.728
Authors: Isabella Kanzler; Nancy Tuchscheerer; Guy Steffens; Sakine Simsekyilmaz; Simone Konschalla; Andreas Kroh; David Simons; Yaw Asare; Andreas Schober; Richard Bucala; Christian Weber; Jürgen Bernhagen; Elisa A Liehn Journal: Basic Res Cardiol Date: 2012-11-09 Impact factor: 17.165